

PKI-402

Catalog No: tcsc0565



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1173204-81-3

Formula:

$C_{29}H_{34}N_{10}O_3$

Pathway:

PI3K/Akt/mTOR;PI3K/Akt/mTOR

Target:

PI3K;mTOR

Purity / Grade:

>98%

Solubility:

DMSO :

Observed Molecular Weight:

570.65

Product Description


PKI-402 is a selective, reversible, ATP-competitive inhibitor of **PI3K**, including PI3K- α mutants, and **mTOR** (**IC₅₀**=2, 3, 7,14 and 16

nM for PI3K α , mTOR, PI3K β , PI3K δ and PI3K γ).

IC₅₀ & Target: IC₅₀: 2 nM (PI3K α), 3 nM (mTOR), 7 nM (PI3K β), 14 nM (PI3K δ), 16 nM (PI3K γ)^[1]

In Vitro: PKI-402 is an equipotent inhibitor of class I PI3K, including the E545K and H1047R PI3K- α mutants (IC₅₀=2, 3 and 3 nM for PI3K α , PI3K α -H1047R and PI3K α -E545K, respectively). PKI-402 causes in vitro growth inhibition of human tumor cell lines derived from a diverse set of human tumor tissues, including breast, brain (glioma), pancreas, and non-small cell lung cancer (NSCLC) tissues. PKI-402 inhibits MDA-MB-361 [breast: Her2⁺ and *PIK3CA* mutant (E545K)], with an IC₅₀ of 6 nM. PKI-402 inhibits HCT116 (K-Ras and *PIK3CA* mutant) with an IC₅₀ of 33 nM^[1].

In Vivo: PKI-402 displays antitumor activity (i.v. route) in breast [MDA-MB-361: Her2⁺ and *PIK3CA* (E545K)], glioma (U87MG and PTEN), and NSCLC (A549; K-Ras and STK11) xenograft models. PKI-402 causes regression in the MDA-MB-361 xenograft model. PKI-402 effect is most pronounced at 100 mg/kg (daily for 5 days, one round), which reduces initial tumor volume and prevents tumor re-growth for 70 days. In MDA-MB-361 tumor tissue, PKI-402 at 100 mg/kg (single dose) fully suppresses p-Akt at both the T308 and the S473 sites at 8 hours and induces cleaved PARP. At 24 hours, p-Akt suppression is still evident, as is cleaved PARP^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!